Skip to main content
editorial
. 2018 Sep 11;35(10):1471–1484. doi: 10.1007/s12325-018-0778-x

Table 2.

Summary of the calculated estimates of the contribution of tapentadol’s opioid component to adverse effects relative to analgesia (its μ-load)

Endpoint Source of data Estimated μ-load (%)
Constipation Animal model (inhibition of GI transit, rat) 30
Clinical trial (cLBP) 40
Clinical trials (OA pain) 33–41
Respiratory depression Animal model (inhibition of CO2 stimulation) 39–46
Clinical pharmacology (VE55)–100/150 mg vs. oxycodone ~ 40